Caxton Corp.
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Caxton Corp. reported 11 stock positions worth $4.3 million. Its top holding was SPDR Gold Shares (GLD) at 64.5% of the portfolio, followed by Berkshire Hathaway Class B (BRK.B, 8.3%) and Spyre Therapeutics (SYRE, 6.8%). Compared with Q3 2025, it opened 2 new positions, sold out of 3, added to 2 and reduced 6. The biggest buy was Berkshire Hathaway Class B (BRK.B, shares +9%) and the biggest sale an exit from Rezolute (RZLT).
- Most Recent 13F
- Q2 2026
- Location
- Princeton, NJ
- CIK
- 0001388551
- Portfolio Value
- $4.3M (Q4 2025)
- SEC Filing
- 0000919574-26-000956 ↗ filed Feb 13, 2026
Holdings Value
Holdings 11 stocks · $4.3M
| GLD SPDR Gold Shares | 64.50% | 6,964 | $2.8M | Reduce -4.4% |
| BRK.B Berkshire Hathaway Inc. Class B | 8.34% | 710 | $357K | Add +9.1% |
| SYRE Spyre Therapeutics Inc. | 6.83% | 8,919 | $292K | New |
| MIND MEDICINE MINDMED INC | 4.91% | 15,688 | $210K | Reduce -41.9% |
| KYTX Kyverna Therapeutics Inc. | 4.12% | 18,773 | $176K | Reduce -18.3% |
| CMPX Compass Therapeutics Inc. | 3.70% | 29,495 | $158K | Reduce -44.9% |
| LXEO Lexeo Therapeutics Inc. | 3.24% | 13,943 | $138K | Reduce -19.6% |
| XFOR X4 Pharmaceuticals Inc. | 1.45% | 15,557 | $62K | New |
| IKT Inhibikase Therapeutics Inc. | 1.36% | 28,453 | $58K | Add +73.6% |
| SABS Sab Biotherapeutics Inc. | 0.92% | 10,527 | $39K | Reduce -3.7% |
| CNTX Context Therapeutics Inc. | 0.63% | 18,403 | $27K | No change |
Portfolio Sells Q3 2025 → Q4 2025
| RZLT Rezolute Inc. | Sold out | 0.00% | −81.70 |
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −1.17 |
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −0.76 |
| SABS Sab Biotherapeutics Inc. | Reduce -3.7% | 0.92% | +0.82 |
| LXEO Lexeo Therapeutics Inc. | Reduce -19.6% | 3.24% | +2.73 |
| CMPX Compass Therapeutics Inc. | Reduce -44.9% | 3.70% | +2.88 |
| MIND MEDICINE MINDMED INC | Reduce -41.9% | 4.91% | +3.52 |
| KYTX Kyverna Therapeutics Inc. | Reduce -18.3% | 4.12% | +3.52 |
| GLD SPDR Gold Shares | Reduce -4.4% | 64.50% | +53.17 |
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $1.9M | SPCX, BRK.B, GOOGL, VOO, BX |
| Q1 2026 | 7 | $4.0M | GLD, BRK.B, KYTX, LXEO, XFOR |
| Q4 2025 | 11 | $4.3M | GLD, BRK.B, SYRE, MIND MEDICINE MINDMED INC, KYTX |
| Q3 2025 | 12 | $22.9M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, ELVN |
| Q2 2025 | 11 | $9.9M | RZLT, GLD, BRK.B, ELVN, MIND MEDICINE MINDMED INC |
| Q1 2025 | 12 | $5.1M | RZLT, GLD, BRK.B, MIND MEDICINE MINDMED INC, BCAX |
| Q4 2024 | 15 | $16.6M | XERS, RZLT, SPY, BRK.B, GLD |
| Q3 2024 | 12 | $24.2M | XERS, RZLT, SPY, BRK.B, BCAX |
| Q2 2024 | 12 | $19.7M | XERS, RZLT, SPY, BRK.B, LXEO |
| Q1 2024 | 11 | $17.6M | XERS, RZLT, SPY, BRK.B, KYTX |